Incyte Corporation (NASDAQ:INCY) announced publication of fresh data from its current ECHO202 study assessing epacadostat in combination with Merck & Co., Inc. (NYSE:MRK)’s Keytruda. The company revealed that abstracts were published by the American Society of Clinical Oncology (ASCO) before the annual meeting scheduled for June 2 – 6 in Chicago. Following this, the stock surged in after-hours trading on Wednesday and the trend could continue on Thursday.
Incyte indicated that its ECHO-202 phase 1/2 trial included efficacy and safety data from non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN) and ovarian cancer (OVC). The company indicated that pooled data on safety from the second phase across cohorts were also disclosed.
Commenting on the developments, the company’s chief medical officer, Steven Stein, said, “We are very pleased to share these new data for epacadostat in combination with pembrolizumab. The combination is well-tolerated and preliminary efficacy outcomes for these cohorts demonstrate encouraging clinical activity, both within and across tumor types, which compares favorably to contemporary data in the second-line setting. These data, including updated data which will be presented at ASCO next month, supported the recently-announced progression of the epacadostat and pembrolizumab combination into pivotal trials in NSCLC, RCC, bladder cancer and SCCHN.”
Incyte revealed that as many as 244 patients were evaluated in a pooled analysis in the second stage trial of ECHO-202 and that less than five percent of the patients faced treatment-related adverse events (TRAE). That included fatigue, rash, diarrhea and nausea. The company indicated that TRAEs led to discontinuation of treatment in three percent of patients in the trial.
Following this, the stock surged 9.76 percent in after-hours trading on Wednesday and the trend could extend on Thursday.